Table 4.
Factors associated with late-onset events (7 months, 1 year, 2 years) by univariate analysis (n: number of patients with AEs at that time point; OR: odds ratio; 95% CI = l: 95% confidence interval; p: p-value for univariate logistic regression).
| Characteristics | Late-Onset AEs (≥2 Years, n = 4) | Late-Onset AEs (≥1 Years, n = 15) | AEs (≥7 Months, n = 20) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | |
| Age (years) | 1.03 | (0.94–1.12) | 0.578 | 0.99 | (0.95–1.03) | 0.545 | 0.97 | (0.93–1.00) | 0.068 |
| Age > 75 yo | 0.59 | (0.06–5.98) | 0.658 | 0.61 | (0.17–2.12) | 0.433 | 0.52 | (0.17–1.63) | 0.264 |
| Male | 0.29 | (0.03–2.93) | 0.296 | 0.77 | (0.25–2.38) | 0.653 | 0.90 | (0.33–2.49) | 0.845 |
| Type of melanoma | |||||||||
| NM vs. others | Not available | 0.969 | 0.60 | (0.12–3.02) | 0.539 | 0.69 | (0.17–2.75) | 0.601 | |
| SSM vs. others | 5.33 | (0.53–53.83) | 0.156 | 4.40 | (1.33–14.56) | 0.016 | 3.42 | (1.19–9.79) | 0.023 |
| Multiple metastatic sites | 0.53 | (0.05–5.33) | 0.589 | 2.18 | (0.70–6.81) | 0.180 | 1.12 | (0.40–3.17) | 0.830 |
| Mutation Status | |||||||||
| NRAS vs. others | 1.42 | (0.19–10.63) | 0.734 | 0.64 | (0.20–2.10) | 0.464 | 0.91 | (0.32–2.55) | 0.853 |
| Wild vs. others | 1.27 | (0.17–9.52) | 0.815 | 1.57 | (0.51–4.84) | 0.437 | 0.79 | (0.28–2.22) | 0.655 |
| Immunotherapy | |||||||||
| IT association | 1.33 | (0.13–13.74) | 0.809 | 0.55 | (0.11–2.73) | 0.464 | 0.63 | (0.16–2.47) | 0.502 |
| Line | |||||||||
| 2nd, 3rd or 4th line | 1.89 | (0.19–19.06) | 0.589 | 5.06 | (1.05–24.26) | 0.043 | 8.13 | (1.73–38.21) | 0.008 |
| Previous IT line | 1.79 | (0.24–13.35) | 0.576 | 2.34 | (0.75–7.32) | 0.144 | 2.78 | (0.98–7.88) | 0.054 |
| Overall response * | |||||||||
| Progressive vs. others | 1.54 | (0.20–11.69) | 0.676 | 0.69 | (0.21–2.32) | 0.550 | 1.00 | (0.34–2.93) | 1.000 |
* data missing from 14 patients.